Cannabis, Anxiety, and Depression: Study Outline

The relationship between cannabis use and mental health has become one of the most pressing questions in contemporary psychiatry and public health policy. As legalization spreads across North America and beyond, millions of individuals now use cannabis—both for medical purposes and recreationally—often citing anxiety and depression as primary reasons for consumption.

This study outline presents a rigorous framework for investigating the causal relationship between cannabis use—particularly examining frequency, potency, and duration of exposure—and the onset and progression of anxiety disorders and depression. The proposed longitudinal cohort design aims to track incident cases over at least five years, addressing critical gaps in current evidence where observational studies dominate and randomized controlled trials remain scarce.

The scope deliberately excludes acute symptom relief studies, focusing instead on long-term mental health trajectories in diverse populations. This includes adolescents and individuals with preexisting vulnerabilities, populations where the stakes of getting policy wrong are highest. By establishing clear methodological standards for studying cannabis to treat mental disorders, this outline serves as both a research protocol and a call for evidence-based approaches to medical cannabis policy.

Introduction: Mental Health, Cannabis Use, and Study Rationale

Mental health disorders represent an enormous global burden that continues to grow. Understanding whether cannabis helps or harms these conditions has never been more urgent.

Prevalence of Anxiety and Depression

The scale of anxiety and depression worldwide demands attention:

These World Health Organization figures represent only diagnosed cases. The true prevalence, including undiagnosed and subclinical presentations, likely exceeds these estimates substantially.

Trends in Medical and Recreational Marijuana

In the United States and Canada, approximately 27 percent of individuals aged 16-65 report medical marijuana use. Roughly half cite mental health symptom management as their primary reason—a widespread self-medication trend that outpaces scientific evidence of efficacy.

Recreational marijuana use has surged following legalization:

• Daily or near-daily use rates have climbed significantly in Canada and parts of the US

• From 2005-2006 to 2015-2016, individuals with depression became 130 percent more likely to use cannabis

• The same population became 216 percent more likely to use cannabis daily

• Medical cannabis trends mirror recreational patterns, with 36.7 percent of surveyed medical users certified for anxiety and 15.7 percent for post traumatic stress disorder

Quality-of-life metrics among these users tell a concerning story. The Functional Assessment of Chronic Illness Therapy-Palliative Care scores show lower emotional and social well-being scores (T-scores below 45) compared to population norms, particularly among those concurrently using opioids or benzodiazepines.

Justifying the Study Given Evidence Gaps

The rationale for this study stems from profound evidence gaps that current research has failed to address. The largest review of medicinal cannabis to date, published March 20, 2026, by University of Sydney researchers analyzing over 100 trials, found:

• No effective treatment for anxiety, depression, or PTSD

• Potential worsening of mental health including psychosis and addiction risks

• Only weak benefits for insomnia or autism-related symptoms

• Little evidence supporting claims of therapeutic benefit for psychiatric disorders

Millions self-treat with cannabis without proven outcomes and often delay evidence-based therapies like cognitive-behavioral therapy or SSRIs.

This sparse evidence base creates an urgent need for well-designed prospective studies that can establish—or refute—causal relationships between cannabis exposure and mental illness.

Background: Mental Disorders, Developing Anxiety, and Cannabis Exposure

Understanding the biological and epidemiological connections between cannabis and mood disorders requires examining multiple levels of evidence, from population studies to neurobiological mechanisms.

Links Between Cannabis Use and Mental Disorders

The relationship between cannabis use and mental disorders appears bidirectional, but evidence increasingly points to cannabis as a risk amplifier rather than a treatment. Habitual use is associated with higher anxiety disorder incidence across multiple study designs.

A critical review reveals a paradox in user experiences:

• 37.5 percent of chronic users report symptom relief via relaxation

• Logistic regression analyses show cannabis abusers exhibit elevated anxiety (measured by State-Trait Anxiety Inventory)

• Physical anhedonia and sensation seeking are higher in users compared to controls

• Self-perceived benefits do not align with objective mental health measures

This disconnect between subjective drug effects and measurable outcomes represents a core challenge for both researchers and clinicians. Patients may genuinely feel better while their underlying condition worsens—a phenomenon that complicates both treatment and study design.

Adolescent Exposure and Risk of Developing Anxiety

Adolescent cannabis exposure carries heightened risks due to neurodevelopmental vulnerability. The developing brain undergoes critical pruning phases during adolescence, making it particularly susceptible to THC’s effects on brain development.

Meta-analyses examining young adults who used cannabis during adolescence reveal:

Longitudinal data from a 15-year Australian cohort demonstrates dose-response relationships:

• Daily cannabis use at age 29: adjusted odds ratio of 2.5 for anxiety disorder onset

• Continued daily use: adjusted odds ratio of 3.2 for anxiety disorders

• Cannabis dependence alone: adjusted odds ratio of 2.2

These findings suggest that adolescent exposure initiates trajectories of increased risk that persist into young adulthood and beyond.

Mechanisms Linking Cannabis to Mood Changes

The endocannabinoid system plays a central role in emotional regulation, and cannabis use disrupts this system in several ways:

THC’s Effects on Neural Circuits:

• THC interacts with CB1 receptors throughout the brain

• This disrupts prefrontal cortex regulation of emotion and stress responses

• Heightened amygdala activity results from impaired top-down control

• Dopamine dysregulation resembles patterns seen in psychosis precursors

CBD’s Potential Counteracting Role:

• CBD may produce anxiolytic effects via 5-HT1A receptor agonism

• However, high-THC formulations predominate in recreational markets

• The ratio of THC to CBD in consumed products often favors anxiety-promoting effects

Developmental Considerations:

• THC alters hippocampal neurogenesis during adolescence

• White matter integrity changes during critical developmental periods

• These structural changes may underlie persistent vulnerability to psychotic disorders and mood disorders

Sponsored

Literature Review: Medical Cannabis and Mental Health Conditions

Evaluating the evidence for cannabis as treatment requires systematic examination of both experimental and observational research. The quality and consistency of findings determine what conclusions clinicians and policymakers can reasonably draw.

Randomized Controlled Trials on Anxiety and Depression

Randomized controlled trials examining medical cannabis for anxiety and depression are limited in number and yield mixed, low-quality evidence.

The 2026 University of Sydney mega-review synthesized findings across dozens of controlled trials:

• No significant symptom reduction for anxiety or depression

• Insufficient evidence to support therapeutic claims

• Potential for harm, including increased psychosis risk

• Methodology concerns across most included studies

A single-blind randomized clinical trial in Massachusetts examined medical marijuana card access:

• Participants with card access increased cannabis use

• Cannabis use disorder symptoms increased in the intervention group

• Depression scores on the Hospital Anxiety and Depression Scale showed no improvement after 12 weeks

• The study suggested access to medical cannabis may cause more harm than benefit

Observational Studies on Long-Term Outcomes

Observational studies, while unable to establish causation definitively, provide crucial information about real-world patterns and long-term trajectories.

Key findings from cohort and cross-sectional studies:

• Daily use worsens anxiety and depression over time (Health Canada guidelines)

• Meta-analyses report OR 1.17 for depression in users versus controls

• Heavy users show OR 1.62 for depression

• Regular use carries 1.5-fold odds for major depressive episode

• Unidirectional risk analyses peg OR 1.33 for depression in youth users

These observational studies consistently point toward increased risk rather than benefit, though residual confounding remains a concern in all non-randomized research.

Evidence Quality for Different Cannabinoids

Evidence quality varies substantially by cannabinoid profile:

Limitations affecting evidence quality across cannabinoid types include:

• Small sample sizes (often n<50)

• Short study durations (4-12 weeks)

• High dropout rates from side effects like sedation

• Heterogeneous dosing and delivery methods

• Variable product composition

Specific Evidence: Anxiety Disorders, PTSD, and Depression Outcomes

Examining specific mental health conditions reveals patterns that inform both clinical practice and research priorities.

Effect Sizes for Anxiety Disorders

Tabulated studies on anxiety disorders show modest or null effect sizes:

Dorard et al. (2008): Self-reports indicate higher anxiety in cannabis abusers despite self-perceived relief. PATH analyses confirm self-medication intent but no causal relief from anxiety symptoms.

Temple et al. (2014): Lifetime anxiety higher in past and current cannabis users (n=316), with effects mediated by self-medication intent. Those using cannabis specifically to reduce anxiety showed worse outcomes than non-users.

For social anxiety disorder and panic disorder, evidence for benefit remains particularly weak. The few studies examining these specific conditions found no significant reduction in disorder symptoms with cannabis use.

RCT Availability for PTSD and Depression

PTSD randomized controlled trials are notably scarce:

• The 2026 review notes insufficient evidence for PTSD treatment

• Potential psychosis risk in vulnerable populations

• No large-scale trials completed to date

• Small pilot studies show mixed results for ptsd symptoms

Depression outcomes similarly lack robust RCT support:

• Reliance on longitudinal data rather than experimental evidence

• Gobbi et al. (2019) meta-analysis represents best available evidence (OR 1.37 for depression post-adolescent use)

• No randomized trial has demonstrated ability to treat depression effectively with cannabis

CBD Versus THC Formulations

The distinction between CBD and THC formulations is crucial for understanding cannabis effects:

CBD Findings:

• Shows promise in anxiety (reduced STAI scores in social anxiety trials)

• 300-600mg doses reduced public speaking anxiety in small studies

• Mechanism likely involves 5-HT1A receptor agonism

• Lacks large-scale RCT confirmation

THC Findings:

• Correlates with increased anxiety trajectories

• Davis et al. (2022) cohort found increased use predicts anxiety rises in men

• Interestingly, anxiety drives use reduction in women (suggesting differential responses)

• Heavy THC use links to depression (OR 1.62)

These divergent profiles suggest that treating all cannabis as equivalent fundamentally mischaracterizes the evidence. Future studies must carefully distinguish cannabinoid profiles.

Study Objectives and Hypotheses: Cannabis Use, Anxiety and Depression

Clear objectives and pre-specified hypotheses strengthen research rigor and prevent post-hoc interpretation bias. This cannabis anxiety depression study establishes explicit aims across primary, secondary, and exploratory domains.

Primary Objective

The primary objective is to quantify the incidence of new-onset anxiety disorders and depression attributable to cannabis use patterns in a prospective cohort.

Primary Hypothesis: Daily and high-potency cannabis users will demonstrate elevated hazard ratios for incident anxiety and depression compared to non-users and occasional users.

Specific predictions include:

• Daily users will show HR ≥1.5 for anxiety disorder onset

• High-potency (>15% THC) users will show additional risk elevation

• Dose-response relationships will be observed across frequency categories

• Effects will be stronger in participants under age 25

Secondary Objective

The secondary objective is to track cannabis use disorder development and characterize its relationship to mental health conditions.

Secondary Hypothesis: Cannabis dependence will develop in a dose-dependent manner, with rates mirroring current observational odds ratios of 2-3 for dependence in heavy users.

This objective addresses the often-overlooked outcome of substance use disorders developing during treatment or self-medication attempts.

Exploratory Aims

Exploratory aims extend the analysis to related phenomena:

1. Withdrawal Trajectory Modeling: Use growth mixture models to characterize cannabis withdrawal symptom patterns, including irritability and insomnia peaking 1-2 days post-cessation

2. Mediation Analysis: Examine whether withdrawal symptoms mediate the relationship between cannabis use and mood disorders

3. Moderation by Demographics: Explore whether age, sex, or baseline characteristics moderate cannabis effects

4. Bidirectional Relationships: Model temporal sequences to determine whether cannabis use precedes mental health changes or vice versa

Methods: Study Design and Participant Selection

Methodological choices determine what conclusions a study can support. The proposed design prioritizes causal inference while maintaining feasibility.

Longitudinal Cohort Design

A longitudinal cohort design over 5-10 years represents the optimal approach for this research question. This design is superior to case-control methods for establishing temporality—a key criterion for causal inference.

Design Advantages:

• Prospective ascertainment of exposure before outcomes

• Ability to calculate incidence rates and hazard ratios

• Temporal sequencing clearly established

• Repeated measures enable trajectory analysis

Inclusion and Exclusion Criteria

Inclusion Criteria:

• Adults aged 18 and older

• Recent cannabis initiation or ongoing exposure

• Willing to complete quarterly assessments

• Access to smartphone or computer for ecological momentary assessment

Exclusion Criteria:

• Baseline anxiety or depression diagnosis (established via MINI or SCID)

• Current treatment for psychiatric disorders

• Other drugs of abuse (excluding alcohol and tobacco)

• Medical conditions affecting cannabinoid metabolism

• Pregnancy or planned pregnancy during study period

Excluding baseline diagnoses is essential for capturing incident cases and avoiding reverse causation.

Recruitment and Sampling

Recruitment sources should ensure representativeness across user types:

• Primary care settings (for medical users)

• Cannabis dispensaries (for both medical and recreational marijuana users)

• Online panels in legal jurisdictions

• Community outreach in diverse neighborhoods

• University and workplace settings for younger demographics

Sample Size Justification: Target n=2000 for 80% power to detect HR=1.5, accounting for expected attrition of 20% over the study period.

Measures: Cannabis Use, Cannabis Withdrawal, and Mental Health Conditions

Standardized measurement is essential for reproducibility and comparison across studies. All instruments should be validated in relevant populations.

Cannabis Use Frequency and Potency

Cannabis use will be operationalized through multiple complementary methods:

Validation Approach: Urinary biomarkers (THC-COOH) collected quarterly to validate self-report accuracy. This addresses known issues with recall bias in substance use reporting.

Methods of administration to capture include:

• Smoked flower

• Vaporized thc products

• Oral thc preparations (edibles)

• Tinctures and oils

• Topical applications

• Cannabis derivatives and concentrates

Validated Scales for Anxiety and Depression

Mental health outcomes will be assessed using established instruments:

Anxiety Assessment:

• GAD-7 (Generalized Anxiety Disorder 7-item scale)

• HAM-A (Hamilton Anxiety Rating Scale) for clinical severity

• STAI (State-Trait Anxiety Inventory) for dimensional assessment

Depression Assessment:

• PHQ-9 (Patient Health Questionnaire 9-item)

• HAM-D for clinical interviews

• BDI-II for research comparisons

Assessment timing: baseline, monthly (brief), and quarterly (comprehensive).

Cannabis Use Disorder Diagnostic Criteria

Screening for cannabis use disorder follows DSM-5 criteria using the CUDIT-R (Cannabis Use Disorder Identification Test-Revised):

• 8-item screening tool

• Score range 0-32

• Score >8 indicates elevated dependence risk

• Administered at baseline and every six months

Full diagnostic assessment via SCID-5 for participants meeting screening threshold.

Cannabis Withdrawal Symptoms

The Marijuana Withdrawal Checklist (MWC) captures withdrawal-related phenomena:

• 18 items rated 0-3 for severity

• Symptoms include irritability, sleep difficulties, anxiety rebound, appetite changes

• Administered during any periods of use cessation

• Captures physiological effects of discontinuation

Additional withdrawal tracking via ecological momentary assessment during quit attempts, capturing real-time symptom fluctuations.

Data Analysis: Modeling, Causality, and Sensitivity Checks

Rigorous analysis requires pre-registration, appropriate statistical methods, and comprehensive sensitivity testing.

Pre-Registration

Primary analysis plan and hypotheses will be pre-registered on OSF (Open Science Framework) before data collection begins. This includes:

• All primary and secondary outcome definitions

• Statistical models to be used

• Handling of missing data

• Criteria for confirmatory versus exploratory analyses

Time-to-Event Models

Cox proportional hazards models will assess incident outcomes:

h(t) = h₀(t) × exp(β₁×cannabis_use β₂×covariates)

Key modeling decisions:

• Time origin: study enrollment

• Event: first diagnosis of anxiety disorder or depression

• Censoring: loss to follow-up, death, study end

• Competing risks: substance use disorders other than cannabis

Confounder Adjustment

Directed acyclic graphs (DAGs) will identify confounders requiring adjustment:

Minimum Adjustment Set:

• Age

• Sex

• Trauma history

• Socioeconomic status

• Family psychiatric history

• Baseline substance use (alcohol, tobacco)

• Educational attainment

Variables on causal pathways (mediators) will be handled separately to avoid over-adjustment.

Sensitivity Analyses

Robustness checks will include:

• Stratification by potency (>15% THC versus lower)

• Stratification by age (<25 versus ≥25)

• Inverse probability weighting for attrition

• Multiple imputation for missing data

• E-values for unmeasured confounding

• Analysis excluding participants with subthreshold symptoms at baseline

Safety Monitoring: Cannabis Use Disorder and Withdrawal Protocols

Research involving substance use requires robust safety monitoring. Participants may experience adverse events related to either cannabis use or cessation.

Routine CUD Screening

Cannabis use disorder screening occurs at every study visit:

• CUDIT-R administered at baseline, 6, 12, 18, 24 months (minimum)

• Score >8 triggers clinical assessment

• Score >12 triggers immediate consultation with addiction specialist

• Referral to addiction services for scores indicating moderate-severe CUD

Screening data collection occurs independent of study participation decisions, ensuring participants can receive treatment without withdrawal from the study.

Withdrawal Symptom Monitoring

Cannabis withdrawal symptoms are tracked via MWC with defined severity thresholds:

Special attention to:

• Sleep quality deterioration

• Anxiety rebound phenomena

• Suicidal ideation (triggers immediate protocol)

• Functional impairment

Referral Pathways

Participants needing treatment receive facilitated referrals:

• Immediate warm handoff for severe symptoms

• List of local addiction and mental health services

• Follow-up to confirm treatment engagement

• Continued study participation offered if clinically appropriate

All adverse events documented and reported per IRB requirements.

Interpretation: Implications for Medical Cannabis and Clinical Practice

Study results will inform multiple stakeholder groups. Interpretation must balance scientific findings with practical applicability.

Medical Cannabis Policy Decisions

Results interpretation must caution against approving medical cannabis for anxiety or depression given:

• The 2026 review’s null findings for efficacy

• Documented psychosis risks

• Cannabis use disorder development

• Alternative treatments with stronger evidence bases

Policy recommendations will emphasize:

Restrictions on high-THC product approvals for mental health indications appear warranted based on current evidence of harm without demonstrated benefit.

For jurisdictions considering medical cannabis expansion, data on incident mental health conditions in users provides crucial risk assessment information.

Clinician-Facing Guidance

Translating findings for clinical practice requires accessible, actionable recommendations:

For Primary Care Providers:

• Screen for cannabis use in patients presenting with anxiety symptoms

• Discuss evidence gaps when patients inquire about medical cannabis

• Prioritize psychotherapy and SSRIs as first-line treatments

• Monitor for cannabis dependence in patients using cannabis for any purpose

For Psychiatrists:

• Cognitive behavioral therapy and evidence-based medications remain standard of care

• Medical use of cannabis for obsessive compulsive disorder, bipolar disorder, or anorexia nervosa lacks supporting evidence

• Cannabis may delay engagement with effective treatments

Prescribing to High-Risk Groups

For high-risk populations, findings likely support absolute contraindications:

• Adolescents (OR>2 for multiple adverse outcomes)

• Individuals with family history of psychosis

• Those with emerging mood symptoms

• Patients with prior substance use disorders

The median age of onset for most mental health conditions overlaps with peak cannabis use years, creating a vulnerable window requiring particular caution.

Limitations, Bias Assessment, and Robustness Checks

Acknowledging limitations strengthens rather than weakens scientific conclusions. Transparency about what the study can and cannot determine guides appropriate interpretation.

Residual Confounding

Despite careful adjustment, unmeasured confounding remains possible:

Genetic Factors:

• COMT variants modulating THC response

• Polygenic risk scores for mental illness

• Genetic predisposition to both cannabis use and mental disorders

Environmental Factors:

• Unmeasured childhood adversity

• Peer network effects

• Concurrent life stressors

Polydrug Use:

• Interaction effects with alcohol

• Concurrent use of other drugs

• Prescription medication interactions

E-values will quantify the magnitude of unmeasured confounding required to explain observed associations.

Self-Reported Cannabis Use Limitations

Self-reported cannabis data introduces several potential biases:

• Recall bias (mitigated by timeline follow-back methods)

• Social desirability bias (particularly in stigmatized contexts)

• Difficulty estimating potency for illicit products

• Underreporting in employment-sensitive situations

Biomarker validation provides partial correction but cannot capture all relevant exposure dimensions (e.g., timing, route, potency).

Generalizability Considerations

Study findings apply most directly to:

• Legal jurisdictions where high-potency products predominate

• Populations with dispensary access

• Adults (adolescent findings require extrapolation)

Findings may differ from:

• Prohibition-era low-THC cohorts

• Medical-only access jurisdictions

• Traditional cannabis use in non-Western contexts

Readers should interpret significant difference findings with appropriate geographic and regulatory context.

Dissemination, Policy Recommendations, and Future Research

Research impact depends on effective communication to relevant audiences. Strategic dissemination amplifies study contributions.

Manuscript Targets

Primary manuscripts will target high-impact psychiatry and addiction journals:

• JAMA Psychiatry

• Addiction

• The Lancet Psychiatry

• American Journal of Psychiatry

Secondary publications for specialized topics:

• Drug and Alcohol Dependence (methods paper)

• Journal of Clinical Psychology (clinician guidance)

• Health Affairs (policy implications)

Data analysis code and anonymized datasets will be shared via institutional repositories to enable replication.

Policy Brief Development

Policy briefs targeting regulatory agencies will emphasize:

For Health Canada:

• Youth protection measures

• Potency restrictions for mental health indications

• Required patient education about evidence gaps

For US FDA:

• Evaluation standards for cannabis-based therapeutics

• Risk communication requirements

• Post-market surveillance priorities

Collaboration with johns hopkins university school of public health and behavioral sciences faculty will strengthen policy translation.

Future Research Priorities

Building on study findings, future research should prioritize:

Randomized Trials of Pure CBD:

• Doses of 600-1500mg/day for anxiety disorders

• Building on small positive signals from preliminary studies

• High quality studies with adequate sample sizes and duration

• Postdoctoral research fellow training in this methodology

Youth-Focused Longitudinal Studies:

• Ecological momentary assessment for real-time use-symptom links

• Developmental trajectory modeling

• Early intervention identification

• Sleep outcomes as potential mediators

Mechanistic Studies:

• Neuroimaging of cannabinoid effects on emotion circuits

• Genetic moderator identification

• Biomarker development for vulnerability

• Cognitive performance monitoring

Appendix: Measurement Tools, Data Management, and Codebook

Reproducibility requires detailed documentation of all procedures. This appendix provides essential technical specifications.

Validated Instruments and Scoring

PHQ-9 (Depression):

• Score range: 0-27

• Minimal: 0-4

• Mild: 5-9

• Moderate: 10-14 (≥10 triggers clinical attention)

• Moderately severe: 15-19

• Severe: 20-27

GAD-7 (Anxiety):

• Score range: 0-21

• Minimal: 0-4

• Mild: 5-9

• Moderate: 10-14 (≥10 triggers clinical attention)

• Severe: 15-21

CUDIT-R (Cannabis Use Disorder):

• Score range: 0-32

• Score >8: elevated dependence risk

• Score >12: probable cannabis use disorder

MWC (Withdrawal):

• 18 items rated 0-3

• Total score range: 0-54

• Captures: irritability, sleep latency changes, appetite loss, anxiety, restlessness

Data Management and Reproducibility

Data Collection Platform: REDCap for secure, HIPAA-compliant data entry

Analysis Environment:

• R (version 4.x) for statistical analysis

• survival package for Cox models

• Multiple imputation via mice package

• Visualization via ggplot2

Example Code Structure:

# Cox proportional hazards model
library(survival)
model <- coxph(Surv(time, event) ~ cannabis_frequency 
               age sex trauma_history ses,
               data = study_data)

Reproducibility Measures:

• All analysis scripts version-controlled via GitHub

• Seed-set analyses for reproducible random processes

• Docker containers for computational environment preservation

• Pre-registration timestamp verification

Codebook Elements:

• Variable names, labels, and value ranges

• Missing data codes and handling rules

• Derived variable construction procedures

• Quality control flag definitions

Key Takeaways

• Current evidence does not support using cannabis to treat anxiety or depression, with the 2026 University of Sydney review finding no effective treatment across over 100 trials

• Daily cannabis use carries adjusted odds ratios of 2.5 or higher for anxiety disorder onset, with adolescent exposure creating particularly elevated risks

• A rigorous longitudinal cohort study tracking 2000+ participants over 5-10 years could establish causal relationships that current observational evidence cannot confirm

• Safety monitoring must include routine screening for cannabis use disorder and cannabis withdrawal symptoms, with clear referral pathways

• Future research should prioritize randomized trials of CBD at therapeutic doses and youth-focused longitudinal studies examining real-time use-symptom relationships

The relationship between cannabis, anxiety, and depression demands rigorous scientific investigation rather than assumption-based policy. As financial relationships between cannabis industry and research institutions come under scrutiny, independent studies with pre-registered protocols become increasingly valuable.

For clinicians, the message remains clear: evidence-based treatments for anxiety and depression—including psychotherapy, SSRIs, and lifestyle interventions—retain their position as first-line approaches. Until high-quality longitudinal studies demonstrate otherwise, cannabis use for mental health conditions remains rarely justified by available evidence.

For researchers and policymakers, this outline provides a framework for generating the data needed to protect public health while respecting individual autonomy. The path forward requires neither prohibition nor uncritical acceptance, but rather the commitment to following evidence wherever it leads.